MINE (chemotherapy)

MINE (chemotherapy) is a chemotherapy regimen used for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. This regimen includes four drugs: Mitoxantrone, Ifosfamide, Etoposide, and Cytarabine.

Overview

MINE chemotherapy is a salvage regimen, which means it is used when first-line treatments have failed or the disease has relapsed. The regimen is typically administered in a hospital setting due to its intensity and the need for supportive care.

Components

The MINE regimen consists of four drugs:

• Mitoxantrone: An anthracenedione antineoplastic agent that intercalates into DNA and produces both single and double strand breaks.
• Ifosfamide: An alkylating agent that interferes with the growth of cancer cells and slows their spread in the body.
• Etoposide: A topoisomerase inhibitor that prevents cells from being able to repair their DNA, leading to cell death.
• Cytarabine: A pyrimidine analog that inhibits the synthesis of DNA.

Treatment Schedule

The MINE regimen is typically administered over a period of four days. The specific dosages and schedule may vary based on the patient's overall health and specific disease characteristics.

Side Effects

Like all chemotherapy regimens, MINE can cause side effects, which can vary from patient to patient. Some common side effects include nausea, vomiting, hair loss, and fatigue. More serious side effects can include infection, bleeding, kidney damage, and heart problems.

See Also

• Chemotherapy
• Non-Hodgkin's lymphoma
• Mitoxantrone
• Ifosfamide
• Etoposide
• Cytarabine

References

MINE (chemotherapy) Resources
Latest articles Most recent articles Ongoing trials	Wikipedia